$MRAI

Marpai, Inc. (MRAI): Entry into a Material Definitive Agreement

Marpai, Inc. (MRAI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 3 ea030013901ex10-1.htm FORM OF SERIES A SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “ Agreement ”) is dated as of July 29, 2026, by and among Marpai Inc., a Delaware corporation (the “ Company ”), and

Original reporting
Published Jul 31, 2026, 9:29 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 31, 2026, 9:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$MRAI
Neutral
medium confidence
Mentioned
$MRAI
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$MRAINeutralMed
01

Why it matters

This is a primary-source disclosure of a new equity raise framework, with stated minimum and maximum Preferred Stock proceeds ($2M to $5M). The market will focus on dilution mechanics and whether the deal closes on schedule.

02

Market read

A defined-range Series A Preferred Stock financing is disclosed, which can drive near-term repricing around dilution and capital runway expectations once full terms are reviewed.

03

What to watch

Traders will need the missing exhibits details (conversion price, discount, liquidation preference, investor rights, and closing conditions) to judge dilution and downside protection.

Relevance 6/10Novelty 6/10Timing: filed after-hours on 2026-07-31, for next-session trading review

Background

The 8-K reports Item 1.01 entry into a material definitive agreement and Item 3.02 unregistered sales of equity securities, referencing a Series A Securities Purchase Agreement dated July 29, 2026.

Company-level read

Ticker impact

$MRAINeutralMedium confidence
Context

Marpai, Inc. filed an 8-K disclosing entry into a Series A securities purchase agreement, including a $2M to $5M Preferred Stock sale range.

Expected impact

Near-term bias depends on pricing terms and investor participation, but dilution risk typically pressures the stock until details are digested.

Evidence & confidence

The excerpt confirms a material definitive agreement and an unregistered sale of equity securities, but it does not include the purchase price, conversion terms, or closing outcome, limiting precision on magnitude and direction.

Market effects

Adds another small-cap financing datapoint, but no sector-wide regulatory or competitive signal is disclosed in the excerpt.

No regional macro or cross-border impact is described.

No global market linkage is stated beyond standard securities-law language.

Counterpoint

If the Series A terms are favorable (e.g., limited dilution, strong investor quality, or non-dilutive structure), the financing could reduce liquidity risk and support the stock.

Key entities

  • Marpai, Inc.

    Delaware corporation filing the 8-K and entering the Series A securities purchase agreement.

  • Mitchell Family Trust II

    Identified as the Lead Investor in the agreement.

Related articles

$MRAIMedAI 8/10

Marpai Announces $12 Million Private Placement led by Mitchell Companies

Marpai, Inc. (OTCQX: MRAI) said it completed securities purchase agreements for a $12 million private placement of newly designated convertible preferred stock led by Mitchell Companies. The deal sold 12,100 shares at $1,000 each with a $1.00 initial conversion price. Preferred holders receive an 8% dividend in common shares and convert on a liquidity event or qualified public offering.

$ITWMed

Illinois Tool Works Authorizes $6 Bln Buyback

Illinois Tool Works (ITW) said its board authorized a new share repurchase program of up to $6 billion. The board also approved a 7% increase in its regular annual cash dividend to $6.88 per share, effective with the Q4 dividend of $1.72 payable Oct. 9, 2026. ITW closed at $296.66 on Friday.

$JNJMed

Money talcs: Why J&J offered $5.5bn to end cancer cases

Johnson & Johnson is offering $5.5 billion to settle most of more than 70,000 pending talc-related cancer lawsuits, according to the company. Claims allege ovarian cancer or mesothelioma linked to asbestos-contaminated talc. J&J denies wrongdoing and says cases lack merit. Prior orders include $966m (LA) and $1.5bn (Baltimore), with appeals planned.

$AAPLMed

Trump Tariff Refunds Just Topped $100 Billion, and These Companies Are Receiving Some of the Largest Checks

The U.S. Supreme Court invalidated Trump IEEPA tariffs, leaving the administration to refund about $166 billion. By Aug. 4, refunds exceeded $100 billion. Apple received $2.19 billion, Amazon $600 million, and others including Walmart ($2.4B), Ford ($1.3B), GM ($500M), and Costco (~$2B) are expected to receive large checks. New Section 301 tariffs may affect prices.

$MTZMed

Is MasTec’s Debt Raise and Upgraded Guidance Altering The Investment Case For MasTec (MTZ)?

MasTec (MTZ) completed a $647.76 million fixed-rate senior unsecured notes offering with a 5.85% coupon due Sept. 30, 2036. The company reported Q2 2026 sales of $4,373.55 million and net income of $130.12 million, and raised full-year 2026 revenue guidance to $18.2 billion and GAAP net income to $539 million, citing balance-sheet flexibility and governance updates.